Drug Information

Drug General Information
Drug ID
D04WPG
Former ID
DAP000831
Drug Name
Valproic Acid
Synonyms
Avugane; Baceca; Convulex; Convulsofin; Depakene; Depakin; Depakine; Deproic; Dipropylacetate; Ergenyl; Mylproin; Savicol; Stavzor; VPA; Valproate; Valproinsaeure; Vupral; Acide valproique; Acido valproico; Acidum valproicum; Depakin chrono; Depakine chrono; Dipropyl Acetate; Dipropylacetic acid; Med Valproic; Myproic Acid; Propylvaleric acid; Semisodium Valproate; Valproic acid USP; Abbott 44090; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Convulex (TN); Depacon (TN); Depakene (TN); Depakote (TM); Depakote (TN); Depakote ER (TN); Dom-Valproic; Encorate (TN); Epilim (TN); Epival (TN); G2M-777; Kyselina 2-propylvalerova; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Stavzor (TN); Valproic acid (USP); Winthrop (TN); Di-n-propylacetic acid; Di-n-propylessigsaeure; Di-n-propylessigsaure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, Sodium Salt (2:1); 2 PP (base); 2-Propylpentanoic acid; 2-Propylvaleric acid; 2-n-Propyl-n-valeric acid; 4-Heptanecarboxylic acid
Drug Type
Small molecular drug
Indication Epilepsy [ICD10:G40] Approved [536447], [542039], [551871]
Therapeutic Class
Anticonvulsants
Company
Abbott Laboratories; TopoTarget
Structure
Download
2D MOL

3D MOL
Formula
C8H16O2
InChI
InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
InChIKey
NIJJYAXOARWZEE-UHFFFAOYSA-N
CAS Number
CAS 99-66-1
PubChem Compound ID
3121
PubChem Substance ID
9394, 399407, 621684, 3138784, 4918409, 7847465, 7980632, 8151988, 10539166, 11335448, 11360687, 11363415, 11364691, 11365977, 11367253, 11368539, 11369815, 11372725, 11372856, 11374010, 11375415, 11376701, 11377978, 11461659, 11484648, 11488762, 11491548, 11492191, 11494335, 12015354, 14710660, 15321539, 17389523, 24898751, 26697333, 26752920, 26752921, 29222263, 46260925, 46505925, 48416692, 48424277, 48425730, 49635685, 49640649, 49856166, 50062089, 50105536, 53788878, 56310655
ChEBI ID
ChEBI:39867
SuperDrug ATC ID
N03AG01
SuperDrug CAS ID
cas=000099661
Target and Pathway
Target(s) Histone deacetylase Target Info Inhibitor [535221], [536272], [537490], [537523], [537552]
References
Ref 536447Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 542039(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535221The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-50.
Ref 536272Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
Ref 537490Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Jun 16.
Ref 537523Histone Deacetylase 2 is a Key Regulator of Diabetes and Transforming Growth Factor-{beta}1-Induced Renal Injury. Am J Physiol Renal Physiol. 2009 Jun 24.
Ref 537552Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.